• The Sarcoma Foundation of America Clinical Trial Navigating Service
• Clinical Trials Resource Center
• TH-302 Enrolling in Soft-Tissue Sarcoma
• Trabectedin or Dacarbazine for the Treatment of Patients with Advanced Liposarcoma or Leiomyosarcoma
• Trivalent Vaccine for Sarcoma
• Sarcoma Alliance for Research through Collaboration (SARC)
• Patient Resources
The Sarcoma Foundation of America Clinical Trial Navigating Service offers patients, caregivers and health care professionals up-to-date information about sarcoma cancer clinical trials throughout the United States and Canada. The service is provided in collaboration with EmergingMed and will help you quickly search for clinical trial options that match your specific diagnosis and treatment history.
This free and confidential service is designed to allow you to begin the search process online. However, we recommend that visitors begin the process by calling our toll-free number: 800-536-8718 or go to SFA Clinical Trial Navigating Service
Welcome to the Sarcoma Foundation of America’s Clinical Trials Resource Center presented in partnership with CenterWatch.com, the leading publisher of information on clinical research for patients and their advocates. Please click on the links below to learn more about clinical research and new medical therapies.
Actively Recruiting Clinical Trials*
*for a comprehensive list, please go to the Patient Resource section at the bottom of the page.
Threshold Pharmaceuticals, in collaboration with SARC, has initiated a randomized Phase 3 trial of TH-302 combined with doxorubicin for the treatment of patients with locally advanced unresectable or metastatic soft tissue sarcoma. Eligible patients have the following subtypes: synovial sarcoma, high grade fibrosarcoma, undifferentiated sarcoma; sarcoma not otherwise specified (NOS), liposarcoma, leiomyosarcoma (excluding GIST), angiosarcoma (excluding Kaposi’s sarcoma), malignant peripheral nerve sheath tumor, pleomorphic rhabdomyosarcoma, myxofibrosarcoma, epithelioid sarcoma, and undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma (MFH) (including pleomorphic, giant cell, myxoid and inflammatory forms). Additional information may be found at http://www.thresholdpharm.com or clinicaltrials.gov.
Janssen Research & Development, L.L.C. is conducting a Phase 3 clinical trial for trabectedin or dacarbazine in patients with liposarcoma or leiomyosarcoma. This is a randomized (study drug assigned by chance), open-label (all patients and study staff know the identity of the assigned study drug), active-controlled (comparing to a different drug used for the same condition), parallel-group (different treatment groups continue with separate treatments throughout the study), multicenter study. This study will be divided into three phases, screening, treatment, and follow-up. During screening, potential patients will be assessed for study eligibility after providing signed informed consent. During the treatment phase, patients will receive study drug once every 3 weeks, until disease progression or signs of toxicity. Assessments will be performed to evaluate the effectiveness of the drug, and patient safety will be monitored. During the follow-up phase, after the last dose of study drug, clinical outcomes for patients will be evaluated. Trabectedin will be administered at a dose of 1.5 mg/m2 through a catheter into a large vein as a 24-hour intravenous (IV) infusion, once every 3 weeks, until disease progression or signs of toxicity. Dacarbazine will be administered at a dose of 1.0 g/m2 as a 20 to 120-minute infusion, once every 3 weeks, until disease progression or signs of toxicity. For more information on this study, please visit http://www.l-sarcomastudy.com or http://www.clinicaltrials.gov (Identifier # NCT01343277).
MabVax Therapeutics is actively recruiting patients for a Phase 2 sarcoma vaccine trial who have recently been treated for metastatic sarcoma and whose status is “No Evidence of Disease” or NED. The patients in the study will be randomized to receive either a vaccine that is combined with an immune system stimulant or the immune system stimulant alone. The immune system stimulant is called OPT-821 and is an immunological booster. If the trivalent vaccine can stimulate the patient’s immune system to develop antibodies which recognize and target the GM2, GD2 and GM3 sugars that are over expressed on the surface of most sarcomas, then the patient’s antibodies could attack and kill any remaining sarcoma cells potentially preventing the recurrence of sarcoma. For more information about the trial, please visit the clinical trial overview.
SARC is a non-profit organization providing the infrastructure for collaboration between physicians, researchers, and medical institutions from across the world who are engaged in clinical research for development of new standards of patient treatment, education, and prevention. To find out more about SARC and a listing of our current clinical trials, please go to the SARC Trials Website.
About Clinical Research
Background information about the clinical trials process and what to expect when you volunteer to participate in a clinical trial. Here, you’ll find answers to frequently asked questions about clinical trials and also suggestions for where to find more information.
CenterWatch Clinical Trials Listing Service
Database of industry sponsored clinical trial listings for Sarcoma.
Listing of Studies at ClinicalTrials.gov
Link to ClinicalTrials.gov, a comprehensive listing of federally and privately supported clinical trials. The U.S. National Institutes of Health (NIH), through its National Library of Medicine (NLM), has developed this site in collaboration with the Food and Drug Administration (FDA).
Profiles of Research Centers
Detailed descriptions of centers that conduct clinical research in the field of Oncology. Profiles include an overview of each center, descriptions of clinical research investigators and staff, and links to currently enrolling clinical research studies.
New FDA Drug Approvals
Database of new medical treatments approved by the FDA since 1995. Detailed summary descriptions for each drug are provided including drug name; manufacturer; mechanism of action; clinical trial results, and side effect profile.
CenterWatch Research Headlines
Here you’ll find links to news articles and reports on recent advances in clinical research. This section is updated weekly and the information has been published in CenterWatch publications during the past weeks.
Descriptions of all of CenterWatch’s publications for patients and for clinical research professionals.
Coalition of National Cancer Cooperative Groups
The Coalition’s website provides a wealth of information about cancer clinical trials. Website features include:
• TrialCheck, a clinical trials search engine
• Cancer Research: A Guide to Cancer Clinical Trials, an interactive educational program
• Print materials for ordering
• Discussion with oncology experts
• Patient discussion forum
Clinical Trials search site
The NCI has developed this premier site. Just type in osteosarcoma, soft tissue sarcoma, etc., or refine the search to your personal interests
This site supplements the NCI site above a little bit, but is incomplete so should not be your sole search site
Information on sarcoma subtypes, treatments, clinical trials, and other important resources for sarcoma patients and families.
Information on the Sarcoma Patient Registry. If you are diagnosed with sarcoma, please consider joining the Registry.
Information on applying for a sarcoma research grant, current research funded by the SFA, and past research grants.